iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced compelling data supporting ProFound AI™ Risk was published in the peer-reviewed journal, Radiology.
NASHUA, N.H., Sept. 15, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced compelling data supporting ProFound AI™ Risk was published in the peer-reviewed journal, Radiology.i ProFound AI Risk is the first and only commercially available clinical decision support tool that provides an accurate two-year breast cancer risk estimation that is personalized for each woman, based solely on a screening mammogram. The technology, which allows for the detection of cancers between screenings, was clinically proven to significantly outperform existing breast cancer risk models.
ProFound AI Risk was created from an exclusive relationship between iCAD and leading researchers at the Karolinska Institutet in Stockholm, Sweden, one of the world’s foremost medical research universities and the home of the Nobel Assembly, which selects the Nobel laureates in Physiology or Medicine. This partnership built upon a previous research agreement whereby researchers at the Karolinska Institutet developed a breast cancer risk prediction model using information identified in mammography images provided by iCAD’s AI solutions.
“ProFound AI Risk and the publication of this supporting study represent a giant leap forward in the realm of breast cancer screening. This first-in-kind solution provides crucial data about patients’ individual risk of developing breast cancer between screenings and empowers clinicians to truly personalize patient care,” according to Michael Klein, Chairman and CEO of iCAD. “This technology may help clinicians tailor unique screening regimens for patients, within country guidelines, and may help reduce unnecessary supplemental screenings for women with low risk.”
ProFound AI Risk software uniquely combines aspects within mammographic images, as well as age and breast density, to provide a highly accurate short-term risk estimation that is specific to each woman. The technology provides clinicians with a two-year breast cancer risk category [low, general, moderate and high] and absolute breast cancer risk score for each patient, based on information garnered from a standard bilateral two-view full field digital mammogram.
“ProFound AI empowers women to participate and advocate for the management of their breast care. There is a growing demand among patients to know more information about their individual risk. According to a recent survey, 87% of women expressed interest in learning about their estimated lifetime risk of breast cancer,ii” according to Stacey Stevens, President of iCAD. “ProFound AI Risk has the potential to revolutionize the way breast cancer risk is assessed and could contribute to the acceleration of breast cancer screening from what has historically been an aged-based screening paradigm to a risk-adapted screening paradigm, unique to each woman.”
ProFound AI Risk is supported by a recent study led by researchers at the Karolinska Institutet based on the prospective screening cohort, KARolinska MAmmography Project for Risk Prediction of Breast Cancer (KARMA), which recruited women from 2011-2017. Of 70,877 participants in the KARMA cohort, 974 women with incident cancers and 9,376 healthy women were sampled. ProFound AI Risk reached an area under the curve (AUC) of 0.73 (95% CI 0.71, 0.74). AUC is a standard performance measurement for AI technology that incorporates sensitivity and specificity into a single metric of overall performance. ProFound AI Risk’s AUC of 0.73 indicates high accuracy for risk assessment.
“The Profound AI Risk model performs better than any other current model,” according to the study’s principal investigator, Per Hall, MD, Professor/Senior Physician at the Karolinska Institutet. “The model is a short term risk model which is an advantage in the screening setting, builds heavily on analyses of mammograms, has a flexibility that allows users to choose variables included in the model, is easy and cheap to implement and has little requirement of staff and systems to manage the data.”
Researchers also found a statistically significant superior performance when comparing the ProFound AI Risk model to existing risk models at two years, such as the Tyrer-Cusick v8 model (+11 points) or GAIL model (+12 points), all including breast density within their calculations. Researchers concluded ProFound AI Risk identified women at high likelihood of being diagnosed with breast cancer within two years of a negative screen and in possible need of supplemental screening.i
“ProFound AI Risk is a powerful tool that may aid in the detection of interval cancers, or lesions that are detected between routine mammography screenings,” according to Dr. Axel Gräwingholt, Radiologie am Theater, Paderborn, Germany. “In my experience using the technology following its CE Mark approval and launch in Europe earlier this year, I have found it offers valuable insights for clinicians who may be looking to provide a stratified risk assessment for patients, and is easy to use compared to other breast cancer risk models.”
ProFound AI Risk is currently available on an introductory basis for 2D mammography and will subsequently be available for the rapidly growing 3D mammography market. It is the latest addition to iCAD’s Breast Health Solutions suite, which includes ProFound AI™ for Digital Breast Tomosynthesis (DBT), ProFound AI™ for 2D Mammography, and software solutions for breast density. ProFound AI Risk was CE marked and launched in Europe at the European Congress of Radiology (ECR) virtual meeting in July 2020.
“Last year we introduced our initiative, Panorama Powered by ProFound AI, and with ProFound AI Risk, this concept is beginning to come to life,” added Mr. Klein. “iCAD continues to bring innovative solutions like this to market, and we look forward to advancing the field of mammography as we are working to further expand the ProFound AI portfolio to include next-generation technology that will also incorporate patient’s prior images.* The ability to correlate patients’ past and present images along with future risk will provide clinicians with a broader panoramic vision for each patient that will enable them to evaluate findings across time and ultimately lead to more tailored and personalized patient care.”
For more information about ProFound AI Risk, visit https://www.icadmed.com/profoundai-risk.html.
*Not yet commercially available
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.
ProFound AI™ is a high-performing workflow solution for 2D and 3D mammography, or digital breast tomosynthesis (DBT), featuring the latest in deep-learning artificial intelligence. In 2018, ProFound AI for Digital Breast Tomosynthesis (DBT) became the first artificial intelligence (AI) software for DBT to be FDA-cleared; it was also CE marked and Health Canada licensed that same year. It offers clinically proven time-savings benefits to radiologists, including a reduction of reading time by 52.7 percent, thereby halving the amount of time it takes radiologists to read 3D mammography datasets. Additionally, ProFound AI for DBT improved radiologist sensitivity by 8 percent and reduced unnecessary patient recall rates by 7.2 percent.iii
The Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is FDA-cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body. It uses a proprietary miniaturized x-ray source to deliver a precise, concentrated dose of radiation directly to the tumor site, while minimizing risk of damage to healthy tissue in nearby areas of the body.
For more information, visit www.icadmed.com and www.xoftinc.com.
Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the ability of ProFound AI Risk to enable clinicians to provide more tailored and personalized patient care, to address a significant unmet need, to provide clinical value, lead to fewer unnecessary biopsies, to be more beneficial for patients, to be accepted by clinicians, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
Contacts:
Media inquiries:
Jessica Burns, iCAD
+1-201-423-4492
jburns@icadmed.com
Investor Relations:
Jeremy Feffer, LifeSci Advisors
+1-212-915-2568
jeremy@lifesciadvisors.com
_______________________
i Eriksson, M., et al. Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening. [published online ahead of print September 8, 2020]. Radiology. Accessed via https://doi.org/10.1148/radiol.2020201620
ii Amornsiripanitch N, Ameri SM, Goldberg RJ. Impact of Age, Race, and Socioeconomic Status on Women’s Perceptions and Preferences Regarding Communication of Estimated Breast Cancer Risk. Academic Radiology. May 2020. Accessed via https://doi.org/10.1016/j.acra.2020.03.041
iii Conant, E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1 (4). Accessed via https://pubs.rsna.org/doi/10.1148/ryai.2019180096
